|
Feb 24
|
Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 24
|
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
|
|
Feb 24
|
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
|
|
Feb 23
|
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025
|
|
Feb 21
|
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
|
|
Feb 19
|
Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025
|
|
Feb 19
|
Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
|
|
Feb 19
|
Q4 2024 Axsome Therapeutics Inc Earnings Call
|
|
Feb 18
|
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript
|
|
Feb 18
|
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 16
|
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
|
|
Feb 11
|
Why Axsome Therapeutics (AXSM) Is Advancing Today
|
|
Feb 11
|
Why Axsome Therapeutics Stock Is Soaring Today
|
|
Feb 11
|
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
|
|
Feb 11
|
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
|
|
Feb 10
|
Why Axsome Therapeutics Stock Is Skyrocketing Today
|
|
Feb 10
|
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
|
|
Feb 10
|
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
|
|
Dec 31
|
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
|
|
Dec 30
|
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
|